Epilepsy Ireland will be making our second ever submission to the National Centre for Pharmacoeconomics over the coming weeks supporting the reimbursement of the anti-epileptic drug ONTOZRY® (Cenobamate).
The medication has been indicated for use in adults living with focal-onset seizures and we are supporting reimbursement as clinical trials for this medication have posted positive results.
If reimbursement is approved, this means the drug will be available under the Long-Term Illness or Medical Card schemes etc to those who are prescribed it.
As part of our submission, we are seeking to capture the experience of people living with focal-onset seizures (also known as partial seizures; simple partial or complex partial).
Furthermore as ONTOZRY® is currently available in Ireland under a compassionate access scheme, we are also keen to capture the experience of those who may be taking this medication as part of their current treatment.
We are appealing to those living with focal-onset seizures and those who have taken the medication to please complete our survey.
This may take some time depending on a person’s individual circumstances/personal feelings. However, every response will be crucial to potentially making a new anti-epileptic drug available to people living with focal-onset seizures in Ireland and we would greatly appreciate if you could take the time to complete our survey.
Further information on ONTOZRY® (Cenobamate) is contained within the introduction of our survey page.
To take our survey, please visit our ONTOZRY® (Cenobamate) NCPE Submission survey on the Surveymonkey website. The survey will close on June 28th.